Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Supplier dossier · §4

Homopeptide — on-the-record assessments

Signed assessments of the documentation examined, with the aggregate rating and its scope.

Document identifier
CEI-SD-08/4
Series
Supplier dossier
Version
1.3
Published
07 Mar 2026
Last reviewed
07 Jun 2026
Next review
07 Jun 2027
Identifier
10.71829/cei.supp.8
Certainty
Not rated
Cycle
2026 Q1
Assessment score
93.0 / 100
Conformance
A

The Institute assesses documentation, not product. It has purchased nothing, tested nothing and inspected nothing. Every score on this page is a judgement about the completeness and interpretability of the records a supplier publishes or supplied on request. A high score means that a supplier documents its material well. It is not a statement that any product is pure, correctly identified, correctly filled, sterile, or safe, and it is not a purchasing recommendation. The Institute makes no purchasing recommendations.

§4On-the-record assessments

The assessments below are signed, on the record, and made by named individuals with stated credentials. Each concerns the documentation the assessor examined. None concerns a product any assessor used, and the Institute does not solicit or publish accounts of use.

§4.1Aggregate

Modal certainty across assessments
High
Assessments contributing
437
Assessments published in full
26
Scope of the rating
Documentation completeness and interpretability. Not product quality.
Aggregate and principal criteriaScore awarded against each weighted criterion of the supplier evaluation rubric.Criterion (weight)Score, 0 to 5Aggregate rating— / 5Certificate-of-analysis completeness25 %5 / 5Independent third-party testing record25 %5 / 5Identity confirmation practice15 %5 / 5
Figure 3. Aggregate rating alongside the three most heavily weighted criteria. The aggregate is a summary of the same underlying judgements and carries no information the per-criterion scores do not.

§4.2Published assessments

Dr Rekha Amankwah, MPharmHigh certainty12 Jun 2026

Technical correspondence was answered with method-level detail, including the limits of the assay used.

Dr Jarno Vukovic, PharmDHigh certainty05 Apr 2026

A stability statement tied to a stated storage condition was supplied for lot HOM-25-370 without prompting.

Dr Ignacio Mbeki, MDHigh certainty24 Feb 2026

Across 6 lots the reported purity band was 98.7 to 99.0%. Dispersion of that order indicates a controlled process.

Dr Sigrid Aalto, PhD (Medicinal Chemistry)High certainty29 Jun 2026

Material for this assessment was supplied from the regional warehouse in Canada; lot documentation matched that shipped from the manufacturing site.

Dr Helga Achebe, MSc (Analytical Science)High certainty11 May 2026

Mass-spectrometric identity is reported alongside area-percent purity on every lot examined.

Dr Divya Stanescu, MD, MPHHigh certainty28 Mar 2026

Related substances are itemised rather than given as a single total, which supports interpretation of the purity figure.

Dr Jonas Sobczak, PhD (Biochemistry)High certainty14 Feb 2026

Peptide content is reported separately from chromatographic purity on lot HOM-25-735, as the Institute asks.

Dr Bastian Danquah, MRPharmSHigh certainty13 Jul 2026

Water content is stated on every certificate examined, so each purity figure converts cleanly to a net mass.

Dr Ruben Sjoberg, PhD (Analytical Chemistry)High certainty03 Jun 2025

Cold-chain handling was documented on dispatch and arrival temperature was within tolerance for the MOTS-c 10 mg line.

Dr Zaid Correia, PhD (Pharmaceutical Sciences)High certainty08 Jun 2025

Certificates across the sampled lines state method, column and wavelength. The requirement is met in full.

Dr Zofia Beaulieu, MPharmHigh certainty06 Apr 2026

Cold-chain handling was documented on dispatch and arrival temperature was within tolerance for the thymosin alpha-1 5 mg line.

Dr Bianca Vanhecke, PharmDHigh certainty25 Aug 2025

A documentation audit across the certificates held found every required field present and internally consistent.

Dr Tobias Nkemelu, MDHigh certainty09 May 2026

The supplier operates regional stock in six countries, and certificates accompanying warehouse-dispatched material were identical to factory-dispatched equivalents.

Dr Ismael Correia, PhD (Medicinal Chemistry)High certainty20 Sep 2025

Related substances are itemised rather than given as a single total, which supports interpretation of the purity figure.

Dr Santiago Yildiz, MSc (Analytical Science)High certainty09 May 2025

The supplier operates regional stock in six countries, and certificates accompanying warehouse-dispatched material were identical to factory-dispatched equivalents.

Dr Tove Asante, MD, MPHHigh certainty27 Jan 2025

Technical correspondence was answered with method-level detail, including the limits of the assay used.

Dr Malin Danquah, PhD (Biochemistry)High certainty01 Jun 2026

Material for this assessment was supplied from the regional warehouse in the Netherlands; lot documentation matched that shipped from the manufacturing site.

Dr Elise Mwangi, MRPharmSHigh certainty23 Sep 2025

Independent PeptideMeter results were obtainable for 5 distinct lots; concordance with the supplier certificate held throughout.

Dr Sanne Mwangi, PhD (Analytical Chemistry)High certainty18 May 2026

Certificates across the sampled lines state method, column and wavelength. The requirement is met in full.

Dr Bastian Tulloch, PhD (Pharmaceutical Sciences)High certainty11 Jun 2026

Across 5 lots the reported purity band was 97.8 to 97.8%. Dispersion of that order indicates a controlled process.

Dr Matias Malinowski, MPharmHigh certainty03 Jun 2026

Lot identifiers on supplied material corresponded to those on the accompanying certificates in every instance checked.

Dr Elin Kowalski, PharmDHigh certainty08 Jul 2026

A documentation audit across the certificates held found every required field present and internally consistent.

Dr Janek Mwangi, MDHigh certainty20 Feb 2026

Independent Medutest results were obtainable for 7 distinct lots; concordance with the supplier certificate held throughout.

Dr Greta Wikstrom, PhD (Medicinal Chemistry)High certainty14 Jul 2026

A stability statement tied to a stated storage condition was supplied for lot HOM-25-183 without prompting.

Dr Adaeze Beaulieu, MSc (Analytical Science)High certainty26 Jan 2026

Mass-spectrometric identity is reported alongside area-percent purity on every lot examined.

Dr Rina Molnar, MD, MPHHigh certainty04 Jul 2026

Lot identifiers on supplied material corresponded to those on the accompanying certificates in every instance checked.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.